If you typed BOPAL into a search box, you are probably building a CRO shortlist. This article uses only what BOPAL publishes (www.bopalcro.com · bopalcro.com/es) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What BOPAL publishes
BOPAL is a Santiago, Chile, contract research organization and regulatory affairs consultancy founded in 2019 by Pablo García, its CEO and a former regulatory manager of the clinical studies unit at Sanofi Chile. It serves the pharmaceutical and biotechnology industry with Phase I–IV trials and lists clinical operations, importer-of-record support for clinical trials, statistics, medical writing, data management, real-world evidence and 24/7 pharmacovigilance. It says it ran Chile's largest COVID-19 vaccine trial, with 3,500 volunteers, and Chile's first trial of an inhaled COVID-19 vaccine. Its regulatory practice includes acting as technical director before Chile's ISP and managing imports with the ISP. The site mentions medical devices only in the founder's background.
BOPAL vs bioaccess®
| Dimension | BOPAL | bioaccess® |
|---|---|---|
| Core focus | Chile drug and vaccine CRO plus regulatory consultancy | First-in-human and early feasibility studies for medical devices |
| Geography | Chile HQ (Santiago); CRO partners in the US, Mexico, Argentina, Peru and Colombia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | Sanitary registration (pharma, bioequivalents, cosmetics), technical direction before ISP and 24/7 pharmacovigilance | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you need a Chile-based CRO for a drug or vaccine study, with ISP regulatory and pharmacovigilance support from the same firm, BOPAL publishes that menu.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including BOPAL, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the BOPAL public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.